Charlotte, NCNCT07291297Now EnrollingIRB Ready

Sarcoma Metastatic Clinical Trial in Charlotte, NC

Access cutting-edge sarcoma metastatic treatment through this clinical trial at a research site in Charlotte. Study-provided care at no cost to qualified participants.

Sponsored by Wake Forest University Health Sciences

Quick Self-Assessment

See if you qualify for this Charlotte location

Preparing your pre-screening questions…

Expert Care in Charlotte

Access sarcoma metastatic specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sarcoma metastatic treatment provided free

Apply for This Charlotte Location

Check if you qualify for this sarcoma metastatic clinical trial in Charlotte, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Charlotte

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Charlotte site if eligible
  4. 4Begin participation

About This Sarcoma Metastatic Study in Charlotte

The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue sarcoma can improve patient outcomes.

Sponsor: Wake Forest University Health Sciences

Who Can Participate

Inclusion Criteria

Advanced unresectable or metastatic/intermediate/high grade soft tissue sarcoma
Age ≥ 18 years at the time of enrollment
Initiating first line systemic therapy for advanced/metastatic disease (treatment naïve for advanced/metastatic disease)
Participants who have not yet initiated first line systemic therapy: expected to initiate front-line therapy within 4 weeks of initiating metformin
Participants who have previously initiated first line systemic therapy: No more than 4 weeks from initiation of first line systemic therapy
Adequate performance status (PS) defined as ECOG PS = 0-2
Adequate renal function
Adequate liver function
Individuals of childbearing potential (ICBP) must have a negative serum pregnancy test within 7 days prior to enrollment. NOTE: Individuals who may become pregnant are considered to have childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause). Metformin is known to be excreted in breast milk and should not be used by nursing mothers.
ICBP and partners of ICBP must not be expecting to conceive and be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of \<1% per year when used consistently and correctly) from the time of informed consent until 30 days after study treatment discontinuation.
Individuals who are having sexual relationships in which their partners may become pregnant must be willing to use condoms from the time of informed consent until 30 days after study treatment discontinuation. For a non-pregnant ICBP partner, contraception recommendations should also be considered.
Ability to ingest oral medications

Exclusion Criteria

Already prescribed and taking metformin at time of diagnosis of advanced unresectable or metastatic disease
Planned enrollment on a treatment clinical trial for first line therapy
Breastfeeding within the duration of anticipated study treatment. NOTE: breast milk cannot be stored for future use while the mother is being treated on study.
History of acute or chronic metabolic acidosis including diabetic ketoacidosis, with or without coma.
Participants previously diagnosed with an additional malignancy must be disease-free for at least five years prior to enrollment. Exceptions include ductal carcinoma in situ (DCIS), basal cell or squamous cell skin cancer and in situ cervical or bladder cancer.
Treatment with any investigational drug within 14 days prior to day 1 of treatment
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin. Participants receiving any medications or substances that are inhibitors or inducers of CYP450 enzyme(s) are ineligible. Lists including medications and substances known or with the potential to interact with the specified CYP450 enzyme(s) isoenzymes. Please refer to https://drug-interactions.medicine.iu.edu/MainTable.aspx for the most current information.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure requiring pharmacologic treatment, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator.
Patients with known brain or active central nervous system (CNS) metastases.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Charlotte?

Yes, this clinical trial (NCT07291297) has an active research site in Charlotte, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sarcoma Metastatic Treatment Options in Charlotte, NC

If you're searching for sarcoma metastatic treatment options in Charlotte, NC, this clinical trial (NCT07291297) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Charlotte research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sarcoma metastatic specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sarcoma metastatic clinical trials near you to find additional studies recruiting in your area.

More Sarcoma Trials in Charlotte, NC

See all sarcoma clinical trials recruiting in Charlotte — not just this study.

Browse Sarcoma Trials in Charlotte →

Browse More Trials by Condition

Sarcoma TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Charlotte?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Charlotte, NC